Our Broad and Disruptive Platform
We are delivering a new class of RNA therapeutics – Antibody Oligonucleotide Conjugates (AOCs™). AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. We have demonstrated preclinical proof of concept for AOCs in multiple tissues and recently demonstrated the first-ever successful targeted delivery of RNA into muscle in humans. We are working to broaden the reach of AOCs beyond skeletal muscle to target other tissues and cell types through both internal discovery efforts and key partnerships.